Urinary Tract Infection Therapeutics Market Report 2025 (Global Edition)

Global Urinary Tract Infection Therapeutics Market Report 2025 Market Size Split by Drug Class Outlook: (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nirtofurans ...

Urinary Tract Infection Therapeutics Market Report Description

We have various report editions of Urinary Tract Infection Therapeutics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Competitive Landscape of the Urinary tract infection therapeutics Market

In the urinary tract infection therapeutics market's competitive landscape, numerous key competitors are driving innovation and growth. These developments reflect a significant advancement in UTI therapeutics, offering new treatment options and diagnostic tools to improve patient outcomes.

In April 2024, the FDA approved Pivya, marking the first new oral antibiotic for uncomplicated UTIs in over two decades. Pivya targets common UTI pathogens, including Escherichia coli, and has been used in Europe for over 40 years. Its U.S. availability is anticipated in 2025. (Source: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uncomplicated-urinary-tract-infections) In June 2024, Awarded the £8 million Longitude Prize, this Swedish company's diagnostic test reduces UTI analysis time from days to under an hour. By enabling rapid detection and appropriate antibiotic selection, it addresses antimicrobial resistance concerns and is currently available in Europe. (Source: https://amr.longitudeprize.org/press-release/rapid-test-uti-wins-8m-longitude-prize-on-amr/#:~:text=In%20June%202024%2C%20Sysmex%20Astrego's,%C2%A38%20million%20as%20winner.&text=%5B9%5D%20Antibiotic%20Susceptibility%20Testing%20or,of%20organisms%20are%20susceptible%20to.)

Top Companies Market Share in Urinary Tract Infection Therapeutics Industry: (In no particular order of Rank)

• Pfizer
• Novartis AG
• Cipla Inc.
• Bayer AG
• AstraZeneca
• Shionogi & Co. Ltd.
• GlaxoSmithKline PLC
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Urinary tract infection therapeutics Market

Which Region Dominates the Urinary Tract Infection Therapeutics Market in 2024?

According to Cognitive Market Research, North America currently dominates the urinary tract infection therapeutics market, and the region is expected to have significant growth during the projected period. The region's advanced healthcare infrastructure and high prevalence of UTIs, particularly among women and older adults. Rising awareness about UTI symptoms and early treatment has boosted demand for effective therapeutics. Additionally, the increasing incidence of complicated UTIs, partly due to antibiotic resistance, has spurred innovation in the pharmaceutical sector, leading to the introduction of advanced antibiotics and combination therapies.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). A growing population and a rising burden of UTIs due to lifestyle changes, urbanization, and increasing healthcare accessibility. Awareness campaigns and improved diagnostic facilities have enhanced treatment rates, especially in urban areas. The surge in antibiotic resistance in developing countries has also necessitated the adoption of newer therapies and better infection control measures.

The current report Scope analyzes Urinary Tract Infection Therapeutics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Urinary Tract Infection Therapeutics Market Analysis

According to Cognitive Market Research, the global Urinary tract infection therapeutics market size was estimated at USD 9214.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 3685.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the urinary tract infection therapeutics market with a market size of USD 2908.10 million in 2024 and is projected to grow at a CAGR of 3.0% during the forecast period. High prevalence of UTIs and robust R&D investments in novel therapeutics.
• The Canada urinary tract infection therapeutics market had a market share of USD 442.30 million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. Increasing awareness and access to advanced diagnostic and treatment options.
• The Mexico urinary tract infection therapeutics market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 335.41 million in 2024.

Europe Urinary Tract Infection Therapeutics Market Analysis

According to Cognitive Market Research, the global urinary tract infection therapeutics market size was estimated at USD 9214.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 2764.35 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.5% from 2024 to 2031.

• The United Kingdom urinary tract infection therapeutics market had a market share of USD 464.41 million in 2024 and is projected to grow at a CAGR of 4.3% during the forecast period. Rising antibiotic resistance and government initiatives on antimicrobial stewardship..
• The France urinary tract infection therapeutics market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD 254.32 million in 2024.
• According to Cognitive Market Research, the German urinary tract infection therapeutics market size was valued at USD 547.34 million in 2024 and is projected to grow at a CAGR of 3.7% during the forecast period. Strong healthcare infrastructure and focus on alternative therapies to combat resistance.
• The Italy urinary tract infection therapeutics market is projected to witness growth at a CAGR of 2.9% during the forecast period, with a market size of USD 237.73 million in 2024.
• The Russia urinary tract infection therapeutics market is projected to witness growth at a CAGR of 2.5% during the forecast period, with a market size of USD 428.47 million in 2024.
• The Spain urinary tract infection therapeutics market is projected to witness growth at a CAGR of 2.6% during the forecast period with a market size of USD 226.68 million in 2024
• The Luxembourg urinary tract infection therapeutics market is projected to witness growth at a CAGR of 3.6% during the forecast period, with a market size of USD 85.69 million in 2024.
• The Portugal urinary tract infection therapeutics market is projected to witness growth at a CAGR of 3.3% during the forecast period, with a market size of USD 58.05 million in 2024.
• The Greece urinary tract infection therapeutics market is projected to witness growth at a CAGR of 3.8% during the forecast period, with a market size of USD 33.17 million in 2024.
• The Rest of Europe's urinary tract infection therapeutics market is projected to witness growth at a CAGR of 2.2% during the forecast period, with a market size of USD 428.47 million in 2024.

Asia Pacific Urinary Tract Infection Therapeutics Market Analysis

According to Cognitive Market Research, the global Urinary tract infection therapeutics market size was estimated at USD 9214.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 2119.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.

• According to Cognitive Market Research, the China urinary tract infection therapeutics market size was valued at USD 953.70 million in 2024 and is projected to grow at a CAGR of 6.5% during the forecast period. Large population base and growing healthcare accessibility in urban and rural areas.
• The Japan urinary tract infection therapeutics market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 292.47 million in 2024.
• The India urinary tract infection therapeutics market had a market share of USD 254.32 million in 2024 and is projected to grow at a CAGR of 8.8% during the forecast period. Rising prevalence of UTIs and increasing affordability of healthcare services.
• The South Korean urinary tract infection therapeutics market is projected to witness growth at a CAGR of 6.1% during the forecast period, with a market size of USD 211.93 million in 2024.
• The Australian urinary tract infection therapeutics market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 110.21 million in 2024.
• The South East Asia urinary tract infection therapeutics market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD 146.23 million in 2024.
• The Rest of Asia Pacific urinary tract infection therapeutics market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 150.47 million in 2024.

South America Urinary Tract Infection Therapeutics Market Analysis

According to Cognitive Market Research, the global Urinary tract infection therapeutics market size was estimated at USD 9214.5 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 460.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil urinary tract infection therapeutics market size was valued at USD 197.19 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. Expanding pharmaceutical sector and initiatives for better healthcare accessibility.
• Argentina's urinary tract infection therapeutics market had a market share of USD 77.40 million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period. Improved healthcare education and rising availability of advanced treatments.
• Colombia urinary tract infection therapeutics market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 41.00 million in 2024.
• Peru urinary tract infection therapeutics market is projected to witness growth at a CAGR of 4.6% during the forecast period, with a market size of USD 37.78 million in 2024.
• Chile urinary tract infection therapeutics market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 33.17 million in 2024.
• The Rest of Latin America's urinary tract infection therapeutics market is projected to witness growth at a CAGR of 3.5% during the forecast period, with a market size of USD 74.18 million in 2024.

Middle East Urinary Tract Infection Therapeutics Market Analysis

According to Cognitive Market Research, the global urinary tract infection therapeutics market size was estimated at USD 9214.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 184.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.

• The GCC Countries' urinary tract infection therapeutics market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 78.88 million in 2024. Urbanization and government investments in modern healthcare infrastructure.
• The Egypt urinary tract infection therapeutics market is projected to witness growth at a CAGR of 5.0% during the forecast period, with a market size of USD 19.35 million in 2024.
• The South Africa urinary tract infection therapeutics market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 29.12 million in 2024. High UTI burden and increasing focus on improving access to essential medicines.
• The Turkey urinary tract infection therapeutics market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 15.85 million in 2024.
• The Nigeria urinary tract infection therapeutics market is projected to witness growth at a CAGR of 3.8% during the forecast period, with a market size of USD 19.35 million in 2024.
• The Rest of the MEA urinary tract infection therapeutics market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 21.75 million in 2024.

Urinary Tract Infection Therapeutics Market Analysis

How are Segments Performing in the Global Urinary Tract Infection Therapeutics Market?

Urinary Tract Infection Therapeutics Market Drug Class Segment Analysis

The nirtofurans (Nitrofurantoin) is the fastest-growing segment in the urinary tract infection therapeutics Market. The rise in antimicrobial stewardship programs and guidelines recommending nitrofurantoin as a first-line therapy further bolsters this growth. Advances in drug formulations, addressing resistance concerns, and the growing demand for safer, targeted therapies are expected to sustain the momentum in these segments.

According to Cognitive Market Research, quinolones urinary tract infection therapeutics are likely to dominate the urinary tract infection therapeutics market over the forecast period. Due to their broad-spectrum activity and effectiveness against complicated and recurrent infections. Quinolones, such as ciprofloxacin, are extensively used for their high penetration in urinary tissues and quick action.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Urinary Tract Infection Therapeutics Industry. Request a Free Sample PDF!

Urinary tract infection therapeutics Market Indication Segment Analysis

In the urinary tract infection therapeutics market, the uncomplicated UTI has been expanding at a rapid pace. The rising incidence among young, healthy adults and greater awareness of early treatment. Advances in telemedicine, over-the-counter medications, and adherence to first-line therapies further bolster the growth of the uncomplicated UTI segment.

According to Cognitive Market Research, the complicated UTI segment holds the largest share of the market. Their higher treatment costs, prolonged treatment courses, and increasing prevalence in ageing populations and patients with comorbidities.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Urinary Tract Infection Therapeutics Distribution Channel Outlook: Segment Analysis

Urinary tract infection therapeutics Market Distribution Channel Segment Analysis

In the urinary tract infection therapeutics market, the rapidly growing sector is the online drug stores category. Enhanced digital platforms and the wider availability of OTC and prescription medicines further accelerate growth in this segment, reflecting a shift in patient behaviour toward digital healthcare solutions.

According to Cognitive Market Research, the hospital pharmacies segment holds the largest market share. Due to their role in managing complicated UTIs requiring specialized prescriptions and inpatient care.

• Hospital Pharmacies
• Gynecology and Urology Clinics
• Drug Stores
• Retail Pharmacies
• Online Drug Stores

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion